Industry association · Netherlands · EU Transparency Register 776438619820-95
9
positions filed
in the 326 files tracked
7
legislative files
of 326 tracked
9
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1205 trade and business associations on this site, they rank #200 by legislative files engaged — a count of participation, not a measure of influence.
0.2
declared lobbying FTE
self-declared
€25K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2015
in the register since
Declares membership of
EuropaBio: https://www.europabio.org/
ICBA: https://internationalbiotech.org/
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
Register category
Trade and business associations
Registered as
Hollandbio
Head office
The Hague, Netherlands
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
hollandbio filed 9 positions between 10 Jun 2025 and 5 Aug 2026, across 7 of the 326 legislative files tracked here, attaching a full position paper 9 times.
A circular economy is indispensable for a future world. By using materials smarter, reducing waste and making the most of raw materials, we are building a society that is not only climate-friendly, but also economically strong and competitive. The urgency to make this transition is widely recognised, but the role of biotech in accelerating it remains underscored.
Filed in Dutch · English published by the European Commission
Hollandbio welcomes the European Commissions Industrial Decarbonisation Accelerator Act (IDA Act). For the Act to succeed, it must recognise biotechnology as one of the key drivers of the transition to climate neutrality. Biotech delivers practical, scalable solutions across sectors from chemicals and materials to food, waste, and carbon use.
IVDR/MDR revision: cautiously clarify a viable route from lab to practice When you are ill, you just want one thing: improve. Prefer to stay healthy. At a time when bespoke health is emerging thanks to advances in diagnostics, disease models and treatment options, hollandbio sees innovative diagnostics that help make bespoke work possible in practice as stumbling away from a forest of rules and procedures, including…
Filed in Dutch · English published by the European Commission
Diagnostics as a key to bespoke health When you are ill, you want only one thing: improve. Prefer to stay healthy. The right treatment at the right time for the right patient is getting closer, thanks to advances in diagnostics and treatments. Only these innovations need to achieve this in practice. At a time when the technology is ready to deliver bespoke health, it is stuck in a forest of rules and procedures.
Filed in Dutch · English published by the European Commission
1 Consultation input — The Hague, 11 August 2025 Transform the EU from company nursery to powerhouse Europe is known as a forward-thinking continent, where knowledge and innovation have been at its core for centuries. What was true then remains relevant today. Yet, we are at risk of being overtaken by countries like the United States and China. That’s unfortunate - and not without consequences.
Opening of the attached position paper · the full paper is on the Commission’s record (source link above)
Hollandbio, the Dutch biotech association, welcomes the ambition to strengthen biotech as one of Europes key technologies for health, sustainability, resilience and economic prosperity. More than ever, global challenges and geopolitics underline biotechs strategic importance.
Europe worked hard to become a leader in biotech. But while the rest of the world is taking the next step, we are blocking ourselves. Innovations get stuck in outdated rules and fragmented regulations, talent moves elsewhere, and other continents capitalize on European breakthroughs.
Biotechnology and biomanufacturing are critical for Europes future competitiveness, sustainability and strategic autonomy. While the EU has a strong scientific base and broad political support for biotechnology, its potential remains underutilised due to persistent structural barriers that limit scale-up, market entry and uptake.
Europe has always been a continent of pioneersturning challenges into opportunities and building a future on knowledge, courage, and collaboration. Our leadership in innovation is no coincidence; its the result of decades of smart investment and bold choices.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Everything on this page comes from hollandbio’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.